Filtered By:
Management: Funding

This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 633 results found since Jan 2013.

Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis
Publication date: Available online 3 September 2016 Source:The Lancet Diabetes & Endocrinology Author(s): Natriuretic Peptides Studies Collaboration Background Guidelines for primary prevention of cardiovascular diseases focus on prediction of coronary heart disease and stroke. We assessed whether or not measurement of N-terminal-pro-B-type natriuretic peptide (NT-proBNP) concentration could enable a more integrated approach than at present by predicting heart failure and enhancing coronary heart disease and stroke risk assessment. Methods In this individual-participant-data meta-analysis, we generated and harmoni...
Source: The Lancet Diabetes and Endocrinology - September 2, 2016 Category: Endocrinology Source Type: research

Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomised open-label phase 2 trial
Publication date: Available online 20 April 2015 Source:The Lancet Neurology Author(s): Annette Compter , H Bart van der Worp , Wouter J Schonewille , Jan Albert Vos , Jelis Boiten , Paul J Nederkoorn , Maarten Uyttenboogaart , Rob T Lo , Ale Algra , L Jaap Kappelle Background Patients with a recent vertebrobasilar transient ischaemic attack or ischaemic stroke and vertebral artery stenosis of at least 50% have a high risk of future vertebrobasilar stroke. Stenting of vertebral artery stenosis is promising, but of uncertain benefit. We investigated the safety and feasibility of stenting of symptomatic vertebral artery st...
Source: The Lancet Neurology - April 21, 2015 Category: Neurology Source Type: research

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Results of trial to determine how to prevent future strokes encouraging
UCLA RESEARCH ALERT   FINDINGS: The results of a major, multicenter clinical trial to determine the best treatment for younger patients who have strokes that are potentially due to a hole in the upper chambers of the heart has provided suggestive but not definitive evidence of the benefit of a new heart hole–closure device.   The trial sought to determine which was the best treatment to prevent further strokes: a combination of closing the hole with a "button" device and anti-clotting medicines, or anti-clotting medicines alone. UCLA was one of the 69 performance sites for the study, called the Recurre...
Source: UCLA Newsroom: Health Sciences - March 20, 2013 Category: Universities & Medical Training Source Type: news

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Publication date: Available online 11 March 2015 Source:The Lancet Author(s): Christian T Ruff , Robert P Giugliano , Eugene Braunwald , David A Morrow , Sabina A Murphy , Julia F Kuder , Naveen Deenadayalu , Petr Jarolim , Joshua Betcher , Minggao Shi , Karen Brown , Indravadan Patel , Michele Mercuri , Elliott M Antman Background New oral anticoagulants for stroke prevention in atrial fibrillation were developed to be given in fixed doses without the need for the routine monitoring that has hindered usage and acceptance of vitamin K antagonists. A concern has emerged, however, that measurement of drug concentration or ...
Source: The Lancet - March 12, 2015 Category: Journals (General) Source Type: research

Neuravi raises $21m Series B for thrombectomy device
Neuravi said today that it raised $21 million in a Series B  round for its Embotrap minimally invasive thrombectomy device. “The intention of the funding round is to launch the device in Europe, to run the Arise program for the U.S., to attempt to bring the device for U.S. approval and to continue to develop further technologies in the field,” CEO Eamon Brady told MassDevice.com. “One of the things Neuravi has done that’s unique to all of our competition is we have launched a huge research effort over the last 5 years in understanding the properties of clots – the cause of ischemic stroke – an...
Source: Mass Device - June 17, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Blood Management Business/Financial News Cardiovascular Catheters Stents Life Sciences Partners Neuravi Limited Source Type: news

Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
Publication date: Available online 24 December 2015 Source:The Lancet Author(s): Dena Ettehad, Connor A Emdin, Amit Kiran, Simon G Anderson, Thomas Callender, Jonathan Emberson, John Chalmers, Anthony Rodgers, Kazem Rahimi Background The benefits of blood pressure lowering treatment for prevention of cardiovascular disease are well established. However, the extent to which these effects differ by baseline blood pressure, presence of comorbidities, or drug class is less clear. We therefore performed a systematic review and meta-analysis to clarify these differences. Method For this systematic review and meta-ana...
Source: The Lancet - December 25, 2015 Category: Journals (General) Source Type: research

Vaginal estradiol use and the risk for cardiovascular mortality
STUDY QUESTION Does the use of post-menopausal vaginal estradiol (VE) affect the mortality risk for coronary heart disease (CHD) and stroke. SUMMARY ANSWER The use of VE reduces the risk for cardiovascular mortality. WHAT IS KNOWN ALREADY A growing number of women use VE for post-menopausal genitourinary symptoms. Although this therapy is intended to have only local effects, estrogen is absorbed into the blood circulation and thus VE use may also have systemic effects. STUDY DESIGN, SIZE, DURATION We studied a nationwide cohort in Finland 1994–2009 during which post-menopausal women (n = 195 756) initiated the use...
Source: Human Reproduction - March 15, 2016 Category: Reproduction Medicine Authors: Mikkola, T. S., Tuomikoski, P., Lyytinen, H., Korhonen, P., Hoti, F., Vattulainen, P., Gissler, M., Ylikorkala, O. Tags: Puberty, Aging and HRT Source Type: research

Silk Road touts TCAR study data
Silk Road Medical disclosed encouraging new clinical data for its Enroute device, which is cleared to help protect the brain from stroke while implanting a transcarotid artery stent. The company said that additional data showed its Enroute transcarotid neuroprotection and stent system, indicated for transcarotid artery revascularization (TCAR), helped improve stroke and death rates in the wake of its FDA sign-off last October. Investigators from Massachusetts General Hospital and elsewhere presented their findings during the 2016 Vascular Annual Meeting of the Society for Vascular Surgery, which was held June 8-11 in Natio...
Source: Mass Device - June 15, 2016 Category: Medical Equipment Authors: Mark Hollmer Tags: Catheters Clinical Trials Stents Vascular Silk Road Medical Inc. Source Type: news

Neuravi raises $16.7m
Neuravi said today it raised $16.7 million (EU €15 million) in a new round of debt financing, with funds slated to support U.S. commercialization and portfolio expansion. Money in the round came from healthcare alternative financing provider IPF Partners, the Galway, Ireland-based company said. Funds raised in the round will be invested into the U.S. commercialization of its products and expanding its stroke treatment portfolio, Neuravi said. “With the recent European launch of the EmboTrap II device and the excellent progress in enrolling our pivotal clinical trial, we are making significant headway in delivering...
Source: Mass Device - November 2, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Blood Management Business/Financial News Vascular Neuravi Limited Source Type: news

Ambient Conditions Prior to Tokyo 2020 Olympic and Paralympic Games: Considerations for Acclimation or Acclimatization Strategies
This study was supported by ZonMw (Project: Thermo Tokyo: Beat the heat), Netherlands Organisation for Scientific Research (NWO) (Project: Citius, Altius, Sanius), and Heatshield, under EU Horizon 2020 grant agreement No 668786. Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acknowledgments The authors thank Dr. Tatsuro Amano (Niigata University, Japan) for his assistance with translating the Japanese Meteorological Agency website. Footnotes ^ https://rdrr.io/g...
Source: Frontiers in Physiology - April 23, 2019 Category: Physiology Source Type: research

Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial
Publication date: Available online 20 December 2017 Source:The Lancet Author(s): Philip M Bath, Lisa J Woodhouse, Jason P Appleton, Maia Beridze, Hanne Christensen, Robert A Dineen, Lelia Duley, Timothy J England, Katie Flaherty, Diane Havard, Stan Heptinstall, Marilyn James, Kailash Krishnan, Hugh S Markus, Alan A Montgomery, Stuart J Pocock, Marc Randall, Annemarei Ranta, Thompson G Robinson, Polly Scutt, Graham S Venables, Nikola Sprigg Background Intensive antiplatelet therapy with three agents might be more effective than guideline treatment for preventing recurrent events in patients with acute cerebral ischaemia. W...
Source: The Lancet - December 21, 2017 Category: General Medicine Source Type: research

Biobanking in a Challenging African Environment: Unique Experience from the SIREN Project.
Authors: Akinyemi RO, Akinwande K, Diala S, Adeleye O, Ajose A, Issa K, Owusu D, Boamah I, Yahaya IS, Jimoh AO, Imoh L, Fakunle G, Akpalu A, Sarfo F, Wahab K, Sanya E, Owolabi L, Obiako R, Osaigbovo G, Komolafe M, Fawale M, Adebayo P, Olowoyo P, Obiabo Y, Sunmonu T, Chukwuonye I, Balogun O, Adeoye B, Oladele F, Olowoniyi P, Adeyemi F, Lezzi A, Falayi AT, Fasanya M, Ogunwale K, Adeola O, Olomu O, Aridegbe O, Laryea R, Uvere E, Faniyan M, Melikam E, Tagge R, Akpa O, Akinyemi J, Arulogun O, Tiwari HK, Ovbiagele B, Owolabi M Abstract Africa was previously insufficiently represented in the emerging discipline of biobank...
Source: Biopreservation and Biobanking - May 9, 2018 Category: Biomedical Science Tags: Biopreserv Biobank Source Type: research

Body-mass index, blood pressure, and cause-specific mortality in India: a prospective cohort study of 500  810 adults
Publication date: July 2018 Source:The Lancet Global Health, Volume 6, Issue 7 Author(s): Vendhan Gajalakshmi, Ben Lacey, Vendhan Kanimozhi, Paul Sherliker, Richard Peto, Sarah Lewington Background The association between cause-specific mortality and body-mass index (BMI) has been studied mainly in high-income countries. We investigated the relations between BMI, systolic blood pressure, and mortality in India. Methods Men and women aged 35 years or older were recruited into a prospective study from the general population in Chennai, India between Jan 1, 1998, and Dec 31, 2001. Participants were interviewed (data collecte...
Source: The Lancet Global Health - June 14, 2018 Category: International Medicine & Public Health Source Type: research

Neurophysiological Analysis of Intermanual Transfer in Motor Learning
In this study, MEPs were induced during the subject’s imaged kinesthetic MI. This involves recalling muscle contraction based on a muscle sensory image and was reported to indicate the activity of brain regions similar to those involved in actual muscle contraction (Ruby and Decety, 2001). In the transfer training group, the muscle sensory image evaluation correlated to the actual task execution with the right hand. As a result, it was easy to recall the kinesthetic MI for the training task, thus affecting MI of the non-trained limbs so that MEP changes occurred in the left hand’s MI. In addition, brain exc...
Source: Frontiers in Human Neuroscience - April 17, 2019 Category: Neuroscience Source Type: research